Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients.

Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-García J, Arnalich F, Mingorance J, Pintado Berniches L, Perona R, Arribas JR.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):102-109. doi: 10.1097/QAI.0000000000001391.

PMID:
28418989
2.

Vocal emotion processing deficits in HIV-infected individuals.

González-Baeza A, Arribas JR, Pérez-Valero I, Monge S, Bayón C, Martín P, Rubio S, Carvajal F.

J Neurovirol. 2017 Apr;23(2):304-312. doi: 10.1007/s13365-016-0501-0. Epub 2016 Dec 9.

PMID:
27943048
3.

Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA.

Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, Gabuzda D, Gisslen M, Beth Joseph S, Letendre S, Mukerji SS, Nath A, Perez-Valero I, Persaud D, Price RW, Rao VR, Sacktor N, Swanstrom R, Winston A, Wojna V, Wright E, Spudich S.

J Virus Erad. 2016 Oct 5;2(4):243-250.

4.

Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.

Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L.

HIV Med. 2016 Oct;17 Suppl 5:3-16. doi: 10.1111/hiv.12440. Review.

PMID:
27714978
5.

Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro.

Stella-Ascariz N, Montejano R, Pintado-Berninches L, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Mingorance J, Perona R, Arribas JR.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):91-94.

PMID:
27552152
6.

Facial Emotion Processing in Aviremic HIV-infected Adults.

González-Baeza A, Carvajal F, Bayón C, Pérez-Valero I, Montes-Ramírez M, Arribas JR.

Arch Clin Neuropsychol. 2016 Aug;31(5):401-10. doi: 10.1093/arclin/acw023. Epub 2016 May 8.

PMID:
27193364
7.

Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid.

Stella-Ascariz N, Montejano R, Martin-Vicente M, Mingorance J, Pérez-Valero I, Bernardino JI, Arribas JR.

Open Forum Infect Dis. 2016 Feb 19;3(1):ofw041. doi: 10.1093/ofid/ofw041. eCollection 2016 Jan.

8.

Second-line antiretroviral therapy and the human factor.

Pérez-Valero I, Arribas JR.

Lancet HIV. 2015 Feb;2(2):e34-5. doi: 10.1016/S2352-3018(15)00003-X. Epub 2015 Jan 20. No abstract available.

PMID:
26424456
9.

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.

Curran A, Pérez-Valero I, Moltó J.

AIDS Rev. 2015 Apr-Jun;17(2):114-20. Review.

PMID:
26035169
10.

Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.

Estébanez M, Bernardino JI, Serrano L, Pérez-Valero I, Zamora FX, Montes-Ramírez ML, González-García JJ, Arribas JR.

Enferm Infecc Microbiol Clin. 2016 Jan;34(1):29-32. doi: 10.1016/j.eimc.2015.01.013. Epub 2015 Feb 27.

PMID:
25735716
11.

Facial emotional processing deficits in long-term HIV-suppressed patients.

Gonzalez-Baeza A, Perez-Valero I, Carvajal-Molina F, Bayon C, Montes-Ramirez M, Bernardino JI, Arribas JR.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19664. doi: 10.7448/IAS.17.4.19664. eCollection 2014.

12.

A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy.

Estébanez M, Stella-Ascariz N, Mingorance J, Pérez-Valero I, González-Baeza A, Bayón C, Lakatos B, Borobia A, Arnalich F, Arribas JR.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):419-23. doi: 10.1097/QAI.0000000000000337.

PMID:
25197825
13.

A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.

Pérez-Valero I, González-Baeza A, Estébanez M, Monge S, Montes-Ramírez ML, Bayón C, Pulido F, Bernardino JI, Zamora FX, González-García JJ, Lagarde M, Hernando A, Arnalich F, Arribas JR.

Clin Infect Dis. 2014 Dec 1;59(11):1627-34. doi: 10.1093/cid/ciu640. Epub 2014 Aug 11.

14.

Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.

Estébanez M, Stella-Ascariz N, Mingorance J, Pérez-Valero I, Bernardino JI, Zamora FX, Montes ML, González-García JJ, Arribas JR.

BMC Infect Dis. 2014 Jul 10;14:379. doi: 10.1186/1471-2334-14-379.

15.

Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy.

Pérez Valero I, González-Baeza A, Montes Ramírez ML.

AIDS Rev. 2014 Apr-Jun;16(2):101-8. Review.

PMID:
24937204
16.

Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.

Monge S, Diez M, Pulido F, Iribarren JA, Campins AA, Arazo P, Montero M, Miro JM, Moreno S, Del Amo J; Spanish AIDS Research Network Cohort (CoRIS).

Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8. doi: 10.5588/ijtld.13.0778.

PMID:
24903942
17.

Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study.

González-Baeza A, Carvajal F, Bayón C, Pérez-Valero I, Estébanez M, Bernardino JI, Monge S, Lagarde M, Hernando A, Arnalich F, Arribas JR.

J Neurovirol. 2014 Aug;20(4):362-70. doi: 10.1007/s13365-014-0251-9. Epub 2014 Apr 24.

PMID:
24760361
18.

Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance.

Montes ML, Schapiro J, Pérez-Valero I, García-Bujalance S, Arribas JR.

AIDS. 2014 Mar 27;28(6):932-4. doi: 10.1097/QAD.0000000000000173. No abstract available.

PMID:
24614067
19.

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.

Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F, Bernardino JI, Zamora FX, Monge S, Gaya F, Lagarde M, Rubio R, Hernando A, Arnalich F, Arribas JR.

PLoS One. 2013 Jul 25;8(7):e69493. doi: 10.1371/journal.pone.0069493. Print 2013.

20.

[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders].

Grupo de expertos del Grupo de Estudio de Sida (GeSIDA) y de la Secretaría del Plan Nacional sobre el Sida (SPNS), Podzamczer Palter D, Muñoz-Moreno JA, Alcolea Rodríguez D, Alonso Villaverde C, Antela López A, Blanch Andreu J, Casado Osorio JL, Galindo Puerto MJ, Garolera i Freixa M, Locutura Rupérez J, Lleó Bisa A, Prats París A, Pérez-Valero I, Portilla Sogorb J, Rovira Cañellas A, Téllez Molina MJ, Tiraboschi JM, Vergara Moragues E, Arribas López JR, Goenaga Sánchez MÁ, de León-Naranjo FL, Martínez Chamorro E, Polo Rodríguez R, Muñoz-Moreno JA, Podzamczer D.

Enferm Infecc Microbiol Clin. 2014 Jan;32(1):37-47. doi: 10.1016/j.eimc.2013.03.005. Epub 2013 Apr 30. Spanish.

PMID:
23642283

Supplemental Content

Loading ...
Support Center